Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections.
Nabriva Therapeutics recently published results of the LEAP2 clinical trial investigating XENLETA™ (lefamulin) as an anti-infective agent in community-acquired bacterial pneumonia (CAPB). The Nabriva publication of phase 3 clinical trial results highlights efficacy of XENLETA™ (lefamulin tablets) as novel, short-course, empiric monotherapy for adults with CABP.
Accelero has been involved in the LEAP2 phase 3 clinical trial for the development and validation of PCR assays detecting several infective pathogens in human sputum specimen.
The results have been published by Alexander E et al in the Journal of the American Medical Association (JAMA), 2019 Sep 27. doi: 10.1001/jama.2019.15468. PubMed ID: 31560372.